FDA Class II Recall: Nephron Sterile Compounding's Sodium Chloride Injection 9% Due to Sterility Concerns
Nephron Sterile Compounding Center LLC initiated a Class II recall for 4,190 bottles of Sodium Chloride Injection 9%, USP, 500 mL, due to potential IV bottle port leakage compromising sterility. This voluntary, firm-initiated recall, D-0257-2025, impacts US nationwide distribution. For procurement and regulatory teams, this highlights critical supplier quality vigilance, especially for 503B outsourcing facilities providing sterile injectables. The recall was terminated on August 14, 2025.
FDA Class II Recall Details: Nephron's Sodium Chloride Injection 9% Faces Sterility Challenge
On February 10, 2025, Nephron Sterile Compounding Center LLC initiated a Class II recall (D-0257-2025) for 4,190 bottles of its Sodium Chloride Injection 9%, USP, 500 mL, Single-Dose IV Bottle, Rx Only. This voluntary, firm-initiated action was prompted by a critical lack of assurance of sterility, specifically due to a potential for leakage at the IV bottle port. For procurement directors and supply chain VPs, this event underscores the paramount importance of robust quality control and supplier qualification for sterile injectable products. Any compromise in container integrity directly threatens patient safety and can lead to significant supply disruptions and reputational damage for downstream healthcare providers and distributors. The affected product, identified by NDC: 69374-334-50, was distributed nationwide across the U.S. and included specific lots: NA4008B (with an expiration date of March 3, 2025) and lots NA4005B & NA4005E (with an expiration date of February 20, 2025). Regulatory affairs heads must ensure that all affected product within their distribution channels has been identified and managed according to FDA guidelines, even though the recall was officially terminated on August 14, 2025. The Class II classification indicates that the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates immediate action for any entity holding or distributing these specific lots.
Operational Profile: Nephron Sterile Compounding Center and 503B Facility Compliance
Nephron Sterile Compounding Center LLC operates as a 503B outsourcing facility, located at 4500 12th Street Ext, West Columbia, SC 29172-3025, United States. As a 503B facility, Nephron is permitted to compound sterile drugs for 'office use' without patient-specific prescriptions, playing a crucial role in the U.S. healthcare supply chain for hospitals and clinics. This designation places a heightened regulatory burden on such facilities, requiring them to comply with current Good Manufacturing Practices (cGMP) to ensure product quality and sterility. For business development executives and regulatory affairs teams, this recall highlights the inherent risks associated with sourcing critical sterile products from compounding facilities, even those operating under the 503B framework. The potential for leakage at the IV bottle port directly challenges the fundamental expectation of sterility for these products. Procurement teams must recognize that while 503B facilities offer flexibility and access to specialized formulations, they also demand rigorous due diligence and ongoing monitoring of their quality systems. The incident with Sodium Chloride Injection 9% serves as a reminder that even established 503B facilities can face significant compliance challenges, necessitating a comprehensive supplier audit program that specifically scrutinizes container closure integrity and sterility assurance protocols.
Regulatory Context and Resolution for Sterile Compounding Quality
The voluntary, firm-initiated nature of Nephron's Sodium Chloride Injection 9% recall, coupled with its termination on August 14, 2025, indicates that the company took corrective actions deemed sufficient by the FDA to address the identified sterility assurance issues related to IV bottle port leakage. For regulatory affairs heads and supply chain VPs, the termination of the recall signifies that the immediate risk associated with the specific recalled lots has been mitigated from a regulatory standpoint. However, the underlying cause of such a critical defect—a potential breach in sterility due to packaging integrity—demands continued vigilance. This event aligns with broader industry challenges in maintaining sterility assurance for compounded and manufactured sterile products. For instance, a parallel event involved Essential Wellness Pharma's Progesterone Injection facing an FDA Class II recall due to similar sterility assurance failures. These incidents collectively underscore the ongoing regulatory scrutiny on sterile product manufacturers and compounders. Procurement directors must interpret recall terminations not as an end to supplier risk, but as an indicator that the supplier has addressed a specific issue. Ongoing supplier relationship management should include verification of root cause analysis and implementation of robust preventative measures to avoid recurrence, ensuring long-term supply chain stability and product quality for critical molecules like Sodium Chloride Injection.